Cargando…

Azithromycin for severe COVID-19

Detalles Bibliográficos
Autores principales:	Oldenburg, Catherine E, Doan, Thuy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833672/ https://www.ncbi.nlm.nih.gov/pubmed/32896293 http://dx.doi.org/10.1016/S0140-6736(20)31863-8

Ejemplares similares

Azithromycin: can its benefit be ruled out in mild COVID-19?
por: Rodríguez-Molinero, Alejandro
Publicado: (2021)

Azithromycin, RECOVERY, and the power of large, simple trials
por: Berwanger, Otavio
Publicado: (2021)

Reduction of Coronavirus Burden With Mass Azithromycin Distribution
por: Doan, Thuy, et al.
Publicado: (2020)

Two years later, azithromycin for COVID-19 and the effect on the heart, is it still relevant?
por: Matoso Laranjo, Sérgio
Publicado: (2022)

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19
por: Oldenburg, Catherine E., et al.
Publicado: (2020)

The association between COVID-19 vaccination and Bell's palsy
por: Cirillo, Nicola, et al.
Publicado: (2022)

Neonatal azithromycin administration for prevention of infant mortality
por: Oldenburg, Catherine E., et al.
Publicado: (2022)

COVID-19 severity and obesity: are MAIT cells a factor?
por: McCarthy, Cormac, et al.
Publicado: (2021)

Observational research on severe COVID-19 in diabetes
por: Stehouwer, Coen D A
Publicado: (2021)

Treatment for severe acute respiratory distress syndrome from COVID-19
por: Matthay, Michael A, et al.
Publicado: (2020)

Clinical course and mortality risk of severe COVID-19
por: Weiss, Paul, et al.
Publicado: (2020)

Epidemiology of severe COVID-19 from South Africa
por: Madhi, Shabir A, et al.
Publicado: (2021)

Are women with asthma at increased risk for severe COVID-19?
por: Fernando, Mario, et al.
Publicado: (2021)

Sulfasalazine: a risk factor for severe COVID-19?
por: Konig, Maximilian F, et al.
Publicado: (2022)

The effects of antihypertensive medications on severity and outcomes of COVID19
por: Agirbasli, Mehmet
Publicado: (2022)

Severe COVID-19 pneumonitis and timing of birth in women
por: Calvert, Clara, et al.
Publicado: (2023)

Severe mental illness and European COVID-19 vaccination strategies
por: De Picker, Livia J, et al.
Publicado: (2021)

A double-masked placebo-controlled trial of azithromycin to prevent child mortality in Burkina Faso, West Africa: Community Health with Azithromycin Trial (CHAT) study protocol
por: Sié, Ali, et al.
Publicado: (2019)

Managing secondary fungal infections in severe COVID-19: how to move forward?
por: Verweij, Paul E, et al.
Publicado: (2022)

Mounting evidence of impaired viral control in severe COVID-19
por: Bermejo-Martin, Jesus F, et al.
Publicado: (2021)

Who, what, and when—effective therapy for severe COVID-19
por: Kelmenson, Daniel A, et al.
Publicado: (2022)

Severe COVID-19 and preexisting hypertension: a matter of age?
por: Yamazaki, Osamu, et al.
Publicado: (2022)

MORDOR II: Persistence of Benefit of Azithromycin for Childhood Mortality
por: Keenan, Jeremy D., et al.
Publicado: (2019)

Effect of Single-dose Azithromycin on Pneumococcal Carriage and Resistance: A Randomized Controlled Trial
por: Coulibaly, Boubacar, et al.
Publicado: (2022)

Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?
por: Zhang, Shen-Ying, et al.
Publicado: (2020)

Will helminth co-infection modulate COVID-19 severity in endemic regions?
por: Bradbury, Richard S., et al.
Publicado: (2020)

Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes
por: Leshem, Eyal, et al.
Publicado: (2021)

A role for interleukin-1 receptor antagonism in severe COVID-19?
por: Tattersall, Rachel S, et al.
Publicado: (2021)

Baricitinib for patients with severe COVID-19—time to change the standard of care?
por: Supady, Alexander, et al.
Publicado: (2022)

Stimulating severe COVID-19: the potential role of GM-CSF antagonism
por: Leavis, Helen L, et al.
Publicado: (2022)

Indirect effect of oral azithromycin on the gut resistome of untreated children: a randomized controlled trial
por: Oldenburg, Catherine E, et al.
Publicado: (2020)

New insights into the association between body-mass index and severe COVID-19
por: Bhaskaran, Krishnan
Publicado: (2021)

Rise in diabetic ketoacidosis during the COVID-19 pandemic: several questions remain
por: Misra, Shivani
Publicado: (2022)

COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2023)

Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic
por: Shen, Bo
Publicado: (2021)

COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions
por: Lascarrou, Jean-Baptiste
Publicado: (2021)

Closing COVID-19 mortality, vaccination, and evidence gaps for those with severe mental illness
por: De Picker, Livia J
Publicado: (2021)

Social vulnerability as a risk factor for death due to severe paediatric COVID-19
por: Mujica, Oscar J, et al.
Publicado: (2021)

VV-ECMO in severe COVID-19: multidimensional perspectives on the use of a complex treatment
por: Teijeiro-Paradis, Ricardo, et al.
Publicado: (2023)

Single-dose azithromycin for child growth in Burkina Faso: a randomized controlled trial
por: Sié, Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7tobipbam4ef64q99dol831o00